Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Facial Lymphatic Drainage

Also known as: MLD, manual lymphatic drainage, lymphatic massage, facial MLD

A manual technique using light, rhythmic, skin-stretching strokes in a set sequence to move interstitial fluid through the superficial lymphatic vessels of the face and neck toward the submental, submandibular, preauricular-parotid and deep cervical node groups.

Evidence status

Limited

The best controlled evidence supports manual lymphatic drainage only as an adjunct to compression for limb lymphoedema, with a small additional reduction in two trials; a 2025 split-mouth trial also found less swelling after third-molar surgery. No controlled trial establishes cosmetic facial depuffing in healthy people, and head-and-neck evidence remains sparse and conflicting. Unexplained swelling or possible lymphatic obstruction needs medical assessment rather than a comfort-focused facial treatment.

What facial lymphatic drainage is, and the types available#

Manual lymphatic drainage (MLD) is defined by the British Lymphology Society as hand-applied pressure delivered in a defined sequence and pattern to facilitate removal of fluid and by-products, including protein. Facial MLD applies that concept to the face and neck. It is distinct from general facial massage, tool-based gua sha, pneumatic compression and the multi-component clinical treatment of lymphoedema.[4]

Recognised schools include Vodder, Casley-Smith, Leduc and fluoroscopy-guided approaches. Their stroke patterns and sequences differ. Pressure and rhythm are not standardised across the literature: the British Lymphology Society found that trials often gave little or no indication of either the pressure applied or the speed of delivery.[4]

Facial drainage maps are useful approximations rather than fixed circuits. Cadaveric work found superficial head-and-neck collectors averaging about 0.2 mm in diameter and lying in the subcutaneous plane, with patterns differing between people and between the two sides of the same person. In healthy participants, indocyanine-green lymphography demonstrated three ipsilateral neck drainage pathways; the study protocol's injection sites were designed around upper cervical, submandibular and submental territories.[3][1]

The lower eyelid has interconnected superficial and deep systems. Superficial collectors run in lateral orbital and nasolabial subcutaneous fat, while deeper collectors run beneath orbicularis oculi; lateral routes reach preauricular and parotid nodes and medial routes reach submandibular nodes. The onward relationship to the cervical chain is anatomically plausible, but no single cited study establishes a universal node-by-node route for every face.[1, 2, 3]i[2]

Use of facial lymphatic drainage in aesthetic practice#

No UK-wide statutory licensing framework specific to cosmetic facial MLD is established. It is not named in any tier of England's proposed non-surgical cosmetic-procedure licensing scheme, which remains a proposal and is not in force. It is not one of the JCCP's five registered modalities, and Wales' four licensed special procedures do not include massage or MLD. Scotland's 2026 Act depends on commencement provisions. The sources reviewed do not establish the position in Northern Ireland, which requires a separate local check.[12]

The practical scope boundary is the claim being made. A comfort-led cosmetic facial or short-lived de-puffing service is different from claiming to treat diagnosed lymphoedema. The latter is a clinical condition normally managed within decongestive lymphatic therapy, in which MLD is only one component alongside compression, skin care and exercise. The British Lymphology Society concludes that evidence is insufficient to support MLD as a stand-alone treatment.[4]

No controlled evidence establishes a benefit from facial MLD after botulinum toxin, dermal filler, microneedling, chemical peeling or radiofrequency, or for reducing bruising or downtime after these procedures. Post-procedure use therefore follows the treating clinician's and product manufacturer's instructions rather than an assumed generic benefit.[no source found]

Contraindications and cautions#

Acute infection of any kind and congestive heart failure are general contraindications to manual decongestive treatment. Hypertension, paralysis, diabetes and bronchial asthma are described as relative contraindications requiring individual assessment. Acute inflammation, unexplained lymph-node enlargement, a suspected thrombosis, rapidly developing swelling or an undiagnosed neck mass also sit outside routine cosmetic treatment.[10]

Malignancy requires nuance. It is often listed as a general contraindication, but the oncology literature reviewed did not support the belief that MLD disseminates or accelerates cancer and argued against automatically withholding it from people with metastasis. That does not turn active, suspected or newly diagnosed malignancy into an aesthetic-practice decision: medical clearance and the oncology or lymphoedema team's plan govern.[10]

A crossover trial of 24 healthy young adults found no change in oxygen saturation, diastolic pressure or cervical range of motion after supraclavicular MLD; small reductions occurred in heart rate with Vodder technique and systolic pressure with Godoy technique. These short-term healthy-volunteer data do not establish safety in decompensated cardiac disease or other contraindicated groups.[9]

Clinical uses and the evidence behind them#

Cosmetic puffiness in healthy adults

No controlled trial establishes that facial MLD improves cosmetic puffiness, facial contour or under-eye appearance in healthy adults. Its cosmetic use is therefore based on physiological plausibility, practitioner experience and short-term appearance or comfort rather than demonstrated durable volume change.[no source found]

The British Lymphology Society also notes that reported benefit may partly reflect the psychological effect of structured human touch rather than lymphatic action. This does not make relaxation unreal; it means relaxation and fluid movement have not been separated experimentally.[4]

Clinical lymphoedema

The most substantial evidence belongs to arm lymphoedema after breast-cancer treatment, not to healthy faces. Across six small trials, the Cochrane review found that adding MLD to compression bandaging produced an additional 7.11 percentage-point reduction (95% CI 1.75–12.47) in two trials totalling 83 participants. The volume-reduction outcome was borderline at P=0.06 and absolute lymphoedema volume was not significant. Cochrane nevertheless concluded that MLD is safe and may add benefit to compression, particularly in mild-to-moderate cases, while calling for confirmation.[5]

The UK's professional-body position is more guarded: evidence is insufficient for MLD as a stand-alone treatment, and head-and-neck evidence is limited in both abundance and quality. These conclusions support specialist integrated care; they do not validate a cosmetic facial claim.[4]

Post-surgical facial swelling

Evidence conflicts by surgical context. A meta-analysis of randomised orthognathic-surgery trials found no significant reduction in facial oedema at 72 hours or 30 days and graded the null finding high-certainty. A 2025 assessor-blinded split-mouth trial in 46 third-molar patients found less 3D-scanned swelling with MLD at day 3 (16.93 versus 26.33) and day 7 (2.79 versus 10.61), plus less pain and trismus; the paper did not report units for the volumetric values, and the paired extractions occurred two weeks apart. These findings do not resolve whether the effect extends to non-surgical aesthetic procedures.[6][7, 6]

Post-filler oedema

Persistent malar or periorbital swelling after hyaluronic-acid filler may be mechanical rather than a simple excess-fluid state. In an ultrasound case series of 17 patients involving 26 eyes, filler was found within the SMAS in 23 eyes; ultrasound-guided removal restored venous flow and improved swelling within minutes. This presentation requires assessment by a suitably qualified injector or prescriber rather than repeated MLD.[11]

Selecting facial lymphatic drainage#

The first selection question is whether the presentation is appropriate for a cosmetic manual technique at all. Bilateral, transient morning puffiness is different from unilateral, painful, inflamed, persistent or progressive swelling. Diagnosed lymphoedema, recent surgery and post-injectable complications each have their own clinical pathway.

Technique names do not establish an evidence hierarchy. Anatomical variation, shallow small-calibre collectors and inconsistent reporting of pressure and rhythm mean that no school can be ranked from the available comparative evidence. The protocol published in one third-molar trial used Vodder circular stroking, stationary circles, pumping and pushing, began at supraclavicular nodes and specified 30–40 mmHg for 40 minutes. Those are study conditions, not a validated generic cosmetic protocol.[1, 4]i[7]

Where treatment follows surgery or an injectable procedure, the instructions of the operating clinician, injector and relevant manufacturer govern. Skinipedia does not provide a universal pressure, sequence, treatment length or course schedule.

Adverse effects and their management#

Expected responses

Slow manual techniques may produce relaxation and small transient autonomic changes. Healthy-volunteer evidence found no clinically important acute physiological disturbance, but it was limited to 24 young adults.[9]

Inappropriate fluid mobilisation

Mobilising fluid centrally is unsuitable during acute infection or decompensated heart failure. New breathlessness, chest symptoms, dizziness, marked malaise or rapidly increasing swelling requires treatment to stop and medical assessment.[10]

Local tissue and procedure complications

Pain, bruising, inflammatory flare or increased swelling is not an expected sign that drainage is “working”. Following recent injectables, manipulation may conflict with the treating clinician's instructions, and no evidence establishes whether early MLD alters product position or distribution. Post-filler malar oedema that persists requires diagnostic assessment.[11]

Referral and scope boundaries#

New, persistent, one-sided or recurrent facial or neck swelling is assessed medically rather than treated as cosmetic puffiness. Referral is also indicated for swelling with pain, erythema, heat, fever, shortness of breath, dental symptoms, visual disturbance, a palpable mass or enlarged nodes.

Diagnosed head-and-neck lymphoedema belongs to an appropriately trained lymphoedema service and an integrated decongestive plan. Active or suspected malignancy, recent cancer treatment and complex post-operative swelling follow the specialist team's instructions. A previous cancer diagnosis alone is not evidence that MLD spreads disease, but it does not remove the need for clinical context.[10]

Persistent swelling after dermal filler belongs to the treating injector or a clinician able to assess product position, vascular and lymphatic flow and the need for hyaluronidase.[11] Aesthetic massage must not delay that assessment.

Mechanism of action#

MLD is intended to alter local interstitial pressure and stimulate lymphangion pumping. Near-infrared fluorescence imaging in arms and legs found an immediate 23–28% rise in apparent lymph velocity and a 9–23% shortening of the interval between propulsion events in lymphoedema patients and healthy controls. That study did not image facial lymphatics.[8]

The effect appears transient. The British Lymphology Society reports that without compression, treated limbs returned fully or partly to pre-treatment volumes within 20–30 minutes, and sustained clinical benefit in lymphoedema depends on immediate compression. Facial cosmetic practice does not generally apply compression, so limb durability cannot be assumed for a face.[4]

Commonly misstated claims#

“Cochrane proves facial lymphatic drainage works.”

Cochrane reviewed arm lymphoedema after breast-cancer treatment, with MLD added to compression. It included no healthy cosmetic facial population.[5]

Supported statement: MLD may add a small swelling-reduction benefit to compression in some limb lymphoedema patients; transfer to cosmetic facial puffiness is unproven.

“Facial MLD is clinically proven to reduce puffiness.”

The British Lymphology Society describes head-and-neck evidence as limited and insufficient.[4] No controlled cosmetic trial in healthy adults is available.

Supported statement: facial MLD is used for short-term comfort and perceived de-puffing, without controlled evidence for durable cosmetic volume change.

“It flushes toxins from the face.”

The professional definition refers to movement of fluid and biochemical waste products such as protein; the evidence does not define a cosmetic “toxin” clearance mechanism.[4]

Supported statement: MLD is intended to facilitate fluid and macromolecule movement through lymphatic pathways.

“Drainage fixes filler-related malar oedema.”

Ultrasound evidence identifies a mechanical veno-lymphatic obstruction by filler in a case series, with rapid improvement after product removal.[11]

Supported statement: persistent post-filler oedema requires injector-led diagnostic assessment; it is not established as a massage-responsive problem.

Areas of remaining uncertainty#

  • Whether facial MLD changes measured facial or periorbital volume in healthy people, and for how long; without controlled measurement, cosmetic benefit cannot be quantified.
  • Whether the pumping response imaged in limbs occurs in facial collectors; until facial imaging exists, the mechanism remains an extrapolation.
  • Which pressure, rhythm or school best engages facial lymphatics; without dose-response or comparative trials, product-like protocol claims are unsupported.
  • Why orthognathic meta-analysis and third-molar trial findings disagree; until the difference is explained, post-surgical results cannot be generalised across procedures.
  • Whether early manipulation changes injectable-product distribution; in the absence of evidence, the injector's and manufacturer's instructions remain controlling.

Frequently asked questions#

Is facial lymphatic drainage proven for cosmetic puffiness?

No controlled trial in healthy cosmetic clients is available. Short-lived perceived benefit is plausible, but its size and duration are unknown.

Is it the same as treatment for lymphoedema?

No. Clinical lymphoedema management is multi-component and specialist-led; MLD is one part rather than a stand-alone facial treatment.[4, 5]

Can it be used after filler?

Only within the treating injector's and product manufacturer's instructions. Persistent malar or under-eye swelling requires injector-led assessment rather than repeated massage.[11]

Does a cancer history always exclude treatment?

No evidence reviewed shows that MLD disseminates cancer, but active, suspected or recently treated disease requires the oncology or lymphoedema team's decision.[10]

How long does a drainage effect last?

No facial cosmetic duration has been established. Limb evidence found partial or full return toward baseline within 20–30 minutes without compression.[4]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Pan WR, Suami H, Taylor GI. Lymphatic drainage of the superficial tissues of the head and neck: anatomical study and clinical implications. Plast Reconstr Surg. 2008 May;121(5):1614-1624.Ex vivoTier 3Supports: Cadaveric injection study: 18 halves of the superficial tissues of the head and neck from 9 fresh human cadavers, studied over 20 months using 6% hydrogen peroxide (with and without India ink) to locate lymphatics, then injected with a radiopaque lead oxide mixture. Findings: lymph capillaries arise from skin and galea and drain sequentially into precollecting vessels, collecting lymphatics and first-tier nodes; collecting vessels averaged 0.2 mm in diameter, with 'lymphatic ampullae' structures and inactive lymph nodes along their course; 'different network patterns between subjects and between sides of the same subject'; a lymphaticovenous shunt was found in the occipital region; lymphatics sometimes bypassed the expected nodes to reach sentinel nodes at the root of the neck; anterior neck lymphatics lay above platysma and coursed horizontally, obliquely and upward toward the mandible. SCOPE: cadaveric anatomy in 9 donors, mapping structure only. It says nothing about whether massage moves fluid, and nothing about living, cosmetic or aged faces.Funding / interest: No funding statement in the record retrieved; Jack Brockhoff Reconstructive Plastic Surgery Research Unit, University of Melbourne.
  2. Shoukath S, Taylor GI, Mendelson BC, Corlett RJ, Shayan R, Tourani SS, Ashton MW. The Lymphatic Anatomy of the Lower Eyelid and Conjunctiva and Correlation with Postoperative Chemosis and Edema. Plast Reconstr Surg. 2017 Mar;139(3):628e-637e.Tier 3Supports: Injection, microdissection, histologic and radiologic studies on 12 hemifacial fresh cadaver specimens, plus indocyanine green lymphography in 5 living volunteers. Histology identified lymphatic vessels both superficial and deep to orbicularis oculi. Superficial collectors ran in subcutaneous fat within the lateral orbital and nasolabial fat compartments. Lateral deep collectors ran beneath orbicularis oculi, through the superficial orbicularis retaining ligament into sub-orbicularis oculi fat in the roof of the prezygomatic space, descended to preperiosteal fat at the level of the zygomaticocutaneous ligaments, and travelled adjacent to the facial nerve into preauricular nodes. ICG lymphography in the 5 volunteers confirmed draining pathways laterally to parotid nodes and medially to submandibular nodes. SCOPE: mixed design - 12 cadaveric hemifaces plus 5 live volunteers (so this is NOT purely ex-vivo, and the ICG portion is in-vivo human); the clinical inference (that damaging both systems causes postoperative chemosis and oedema) is the authors' hypothesis, not a tested outcome.Funding / interest: No funding statement in the record retrieved. Taylor Lab / O'Brien Institute academic affiliations; Mendelson practises at a private Centre for Facial Plastic Surgery.
  3. Suami H, Gaitatzis K, Mackie H, Thompson B, Blake FT, Forstner D, Sundaresan P, Skoracki R, Koelmeyer L. A New Indocyanine Green Lymphography Protocol for Assessment of Lymphedema in the Head and Neck. Otolaryngol Head Neck Surg. 2025 Nov;173(5):1302-1306.Tier 3Supports: ICG lymphography in 10 healthy participants and 16 individuals reporting facial or neck swelling after head and neck cancer treatment. Four ICG injection sites were proposed to demonstrate 3 lymphatic territories draining to upper cervical, submandibular and submental nodes. In healthy controls, 3 lymphatic drainage pathways were demonstrated in the ipsilateral neck. In individuals post-neck dissection, dermal backflow was present and 2 additional drainage pathways were visualised to the paraspinal and axillary regions. SCOPE: n=26 total, imaging protocol development, no intervention and no treatment outcome. Confirms healthy facial drainage is ipsilateral and node-directed; does not test manual drainage. Conflict of interest statement: 'None.'Funding / interest: No funding statement in the abstract record; authors based at the Australian Lymphoedema Education Research and Treatment Centre (ALERT), Macquarie University. Declared conflict of interest: 'None.'
  4. Cooper G, Woods M, Noble-Jones R, Borthwick Y, Longhurst S. Manual Lymphatic Drainage Position Document. British Lymphology Society (BLS), September 2024.Tier 1Supports: UK position document built on a 12-month scoping review (searches October 2022 to March 2023, four databases, adults over 18 with chronic oedema/lymphoedema), reviewed by the Lymphoedema Support Network and MLD UK. The document states explicitly that its purpose 'is not to perform a systematic review but to use the principles within the gathering of research studies', with PICO keywords 'entered into four databases'; Appendix A confirms the scoping review ran October 2022 to March 2023. Defines MLD as 'The application of pressure via the hands in a defined sequence and pattern to facilitate the removal of fluid and by-products.' Separately lists the aim of MLD (citing Vairo et al, 2009) as enhancing body dynamics in fluid removal, stimulating the lymphatic system, and accelerating 'the removal of biochemical waste products, such as protein'. The document never specifies which vessel layer is targeted, never uses the words 'contraindication', 'caution', 'cosmetic' or 'facial', and does not use 'deep cervical'. States MLD began with Estrid and Emil Vodder in 1936 and that techniques developing from the Vodder approach include 'Casley-Smith, Leduc, and fluoroscopy guided MLD', each applying the practitioner's hand 'in a variety of sequences'. VERIFICATION NOTE: Foldi is NOT named as a school in this document - 'Foldi' appears only as the Foldi staging scale used as an outcome measure in Deng et al (2019); the document deliberately declines to compare techniques because studies use MLD, outcome measures and equipment differently. Notes of the upper-limb trials that 'There was little or no indication of the pressure used on the tissues by the therapist during MLD or the speed at which the MLD was delivered.' Cites Harris and Piller (2003): fluid volume fell in three cases but 'without external compression, the limb returned to pre-treatment volumes either fully or partially within 20-30 minutes'. Prof Peter Mortimer's foreword states that although MLD 'can enhance lymph flow and soften tissues when applied by an experienced practitioner', 'the changes in lymphatic circulation are transient' and 'Clinical benefit can only be sustained if robust compression therapies are applied immediately after MLD therapy.' Head and neck conclusion: 'the use of MLD in patients with head and neck lymphoedema within the evidence base is limited in terms of abundance and quality... it remains insufficient to fully support the application of MLD in this area.' Upper limb conclusion: 'when MLD is added to other aspects of treatment, it does not provide additional benefit in the objective measurement of limb volume reduction'. Also flags that 'any self-reported benefits related to MLD may relate to improvements in a person's psychological state, rather than the application of MLD.' BLS Statement 1: 'The review found there was insufficient evidence at this time to support the use of MLD alone for the management of lymphoedema.' SCOPE: adults with diagnosed chronic oedema/lymphoedema only. Cosmetic use, facial aesthetics and post-aesthetic-procedure use are entirely outside its scope; the words 'cosmetic', 'facial', 'contraindication' and 'caution' do not appear in the document.Funding / interest: Produced by the British Lymphology Society (UK charity/professional body). No commercial funding declared; no individual author disclosure section in the document.
  5. Ezzo J, Manheimer E, McNeely ML, Howell DM, Weiss R, Johansson KI, Bao T, Bily L, Tuppo CM, Williams AF, Karadibak D. Manual lymphatic drainage for lymphedema following breast cancer treatment. Cochrane Database Syst Rev. 2015 May 21;2015(5):CD003475.Tier 1Supports: Cochrane review of 6 randomised or quasi-randomised trials in women with breast cancer-related lymphoedema of the arm; trials were small, ranging from 24 to 45 participants. MLD plus compression bandaging versus compression bandaging alone (2 trials, 83 participants): bandaging alone gave 30% to 38.6% per cent reduction, with MLD adding a further 7.11% (95% CI 1.75% to 12.47%); volume reduction was borderline (P = 0.06) and absolute lymphoedema volume was not significant. Subgroup analysis suggested mild-to-moderate cases responded better than moderate-to-severe. MLD plus sleeve versus pneumatic pump plus sleeve (1 RCT, 24 participants) favoured MLD for volume reduction (MD 47.00 mL, 95% CI 15.25 to 78.75). MLD plus sleeve versus self-administered simple lymphatic drainage plus sleeve (1 RCT, 31 participants) favoured MLD for lymphoedema volume (MD -230.00 mL, 95% CI -450.84 to -9.16) but not for the other volume outcomes. MLD plus bandaging versus simple lymphatic drainage plus bandaging was not significant (P = 0.10). 'MLD was well tolerated and safe in all trials.' AUTHORS' CONCLUSIONS (carried here so the review is not cited against itself): 'MLD is safe and may offer additional benefit to compression bandaging for swelling reduction... those with mild-to-moderate BCRL may be the ones who benefit from adding MLD to an intensive course of treatment with compression bandaging. This finding, however, needs to be confirmed by randomized data.' Note the 7.11% figure is the PER CENT REDUCTION outcome, not the volume-reduction outcome. For pain and heaviness, '60% to 80% of participants reported feeling better regardless of which treatment they received'. Quality of life results were unusable. In four trials the person measuring swelling was unblinded. SCOPE: arm lymphoedema in women after breast cancer surgery or radiotherapy. No facial, cosmetic or healthy-subject data whatsoever. Conflict of interest statement: 'None known.'Funding / interest: Cochrane review; conflict of interest statement 'None known.' Lead author Ezzo is Research Director of JME Enterprises.
  6. Galdino-Santos L, da Luz-Silva G, Pires ALC, Cademartori MG, Pereira-Cenci T. Perioperative therapies to reduce edema after orthognathic surgery: a systematic review and meta-analysis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2023 Feb;135(2):211-235.Tier 1Supports: Systematic review and meta-analysis of randomised clinical trials only, searched across PubMed, Web of Science, Bireme and Scopus, risk of bias assessed with RoB 2.0; 18 studies included, 8 in the meta-analysis (n = 349). Manual lymphatic drainage showed no significant effect on oedema at 72 hours (95% CI -1.03 to 2.31; P = .45) or at 30 days (95% CI -1.53 to 0.49; P = .49). Low-level laser was also non-significant at every timepoint. Thermotherapy did reduce oedema at 48 hours (95% CI -48.47 to -13.31; P = .0006) and 30 days (95% CI -14.73 to -1.98; P = .01). GRADE: 'the MLD and laser results were rated as high certainty of evidence (no reduction of edema)'. SCOPE: post-surgical facial oedema after orthognathic (jaw) surgery in a hospital setting. This is surgical trauma oedema, not cosmetic puffiness, and not non-surgical aesthetic procedures.Funding / interest: No funding statement in the record retrieved; academic authors, Federal University of Pelotas and Radboud UMC.
  7. Ulu M, Unal N, Sahin O, Kayali Y. Evaluation of the effect of manual lymphatic drainage method on edema, pain and trismus after impacted bilateral mandibular third molar surgery: a randomized clinical trial. BMC Oral Health. 2025 Mar 26;25(1):438.Tier 2Supports: Split-mouth, single-blinded, controlled randomised clinical trial in 46 patients aged 18-26 (mean 18.72, SD 1.50; 14 male, 32 female) with bilaterally symmetrical impacted mandibular third molars. Protocol used the Vodder technique with 'circular stroking, stationary circles, pumping, and pushing techniques', beginning at the supraclavicular lymph nodes and progressing toward the extraction area, with pressure stated as '30-40 mm-Hg from proximal to distal'; 40 minutes of MLD on the day of surgery plus two further sessions at 24-hour intervals. Swelling measured by 3dMD FACE SYSTEM (Table 1): day 3 (T0-T1) 16.93 (SD 1.17) MLD vs 26.33 (SD 1.57) control, P < .001; day 7 (T0-T2) 2.79 vs 10.61, P < .001. VERIFICATION NOTE: the paper states NO UNITS for these volumetric values anywhere in text or table - 'mm3', 'cm3' and 'cc' appear zero times in the full text. Any unit attached to these numbers is an interpolation. VAS pain day 1, 5 vs 7; day 3, 1 vs 3. Maximum mouth opening day 3, 31.70 vs 22.35 mm, P < .001; day 7, 38.57 vs 29.48 mm, P < .001 - though Table 3 is captioned as a comparison of 'the difference in maximum mouth opening amounts', so whether these are absolute openings or changes is ambiguous in the source. Retrospectively registered (NCT06787027, 22/01/2025) although ethics approval dates from 15/02/2018. Funding: 'Not applicable'. Competing interests: 'The authors declare no competing interests.' Full text adds that the two extractions were performed at 2-week intervals (so the split-mouth sides are sequential, not simultaneous), and that outcome assessors 'were not aware of the MLD side' - i.e. assessor-blinded. SCOPE: young dental surgery patients with acute post-extraction oedema; single-blinded, control was routine care rather than sham, and patients could not be blinded to receiving 40 minutes of hands-on treatment. Note the finding contradicts the higher-tier orthognathic meta-analysis (source 6), and the stated pressure figure is this trial's protocol, not a validated or generalisable parameter.Funding / interest: Funding: 'Not applicable' (stated in the paper). Competing interests: 'The authors declare no competing interests.' MLD delivered by a hospital physiotherapist; no device or product manufacturer involved.
  8. Tan IC, Maus EA, Rasmussen JC, Marshall MV, Adams KE, Fife CE, Smith LA, Chan W, Sevick-Muraca EM. Assessment of lymphatic contractile function after manual lymphatic drainage using near-infrared fluorescence imaging. Arch Phys Med Rehabil. 2011 May;92(5):756-764.e1.Tier 3Supports: Exploratory pilot study. 10 subjects with grade I or II lymphoedema (age 18-68) and 12 healthy controls (age 22-59). Indocyanine green 25 micrograms in 0.1 mL injected intradermally in bilateral arms or legs; near-infrared fluorescence images captured before and after MLD. Average apparent lymph velocity increased after MLD in symptomatic limbs (+23%), asymptomatic limbs (+25%) of lymphoedema subjects, and control limbs of healthy subjects (+28%). Average lymphatic propulsion period decreased by 9% (symptomatic), 20% (asymptomatic) and 23% (healthy control) limbs. SCOPE: arms and legs only, no facial imaging. Immediate post-treatment measurement only, so it demonstrates a short-term physiological effect on lymphatic pumping and says nothing about duration, volume change or appearance. n=22 total, pilot.Funding / interest: National Institutes of Health R01 HL092923 and U54 CA136404. Authors certify no party with a direct interest in the results conferred a benefit. The imaging devices were under an FDA-approved investigational protocol at the time - relevant to the measurement technology, not to MLD itself.
  9. Rio-Gonzalez A, Cerezo-Tellez E, Gala-Guirao C, Gonzalez-Fernandez L, Diaz-Meco Conde R, de la Cueva-Reguera M, Guiterrez-Ortega C. Effects of Different Neck Manual Lymphatic Drainage Maneuvers on the Nervous, Cardiovascular, Respiratory and Musculoskeletal Systems in Healthy Students. J Clin Med. 2020 Dec 16;9(12):4062.Tier 2Supports: Four-week cross-sectional, double-blinded randomised crossover trial in 24 healthy participants aged 18-30, recruited from Universidad Europea de Madrid. Each participant received all four interventions in randomised order with a one-week washout: control, placebo, Vodder supraclavicular MLD, and Godoy MLD. No statistically significant differences between groups in oxygen saturation, diastolic blood pressure or cervical range of motion. Heart rate reduction favoured Vodder (P = 0.026). Godoy produced greater reductions in respiratory rate versus control (P = 0.020), systolic blood pressure (P = 0.015) and pressure pain threshold (P < 0.05). Authors conclude MLD 'does not produce any changes in other physiologic outcomes maintaining physiologic values, which may suggest the safety of the technique'. Conflict of interest: 'The authors declare no conflict of interest.' TIER NOTE: re-tiered from 3 to 2 on verification - this is a randomised, double-blinded crossover trial in humans, the same design class as source 7. The paper's own design wording ('4-week cross-sectional, double-blinded randomized clinical trial') is internally inconsistent. SCOPE: 24 healthy young adults, single sessions, physiological outcomes only. No oedema, appearance or facial outcome was measured. This is a safety/physiology signal, not efficacy evidence.Funding / interest: No funding statement in the record retrieved. Two authors are affiliated with Sanamanzana Physiotherapy Clinic, Madrid - a commercial provider of manual therapy, which is the modality under test.
  10. Godette K, Mondry TE, Johnstone PA. Can manual treatment of lymphedema promote metastasis? J Soc Integr Oncol. 2006 Winter;4(1):8-12.Tier 4Supports: Narrative review from a radiation oncology department. States that complete decongestive therapy, which incorporates MLD, has several contraindications: 'Relative contraindications include hypertension, paralysis, diabetes, and bronchial asthma. General contraindications include acute infections of any kind and congestive heart failure.' On malignancy: 'Malignant disease is also widely considered a general contraindication; a current vogue concept is that MLD will lead to dissemination and acceleration of cancer. However, cancer research supports the contention that this therapy does not contribute to spread of disease and should not be withheld from patients with metastasis.' SCOPE: narrative review, not a systematic search; 2006 and therefore dated; written about limb lymphoedema in oncology patients, not facial or cosmetic practice. The contraindication list is expert/textbook convention rather than trial-derived, and this paper is the strongest source located that states it explicitly in the peer-reviewed literature.Funding / interest: No funding statement in the record retrieved; Radiation Oncology Department, Emory University School of Medicine.
  11. Schelke L, Liplavk O, Cotofana S, Shah-Desai S, Velthuis P. Periorbital venous stasis may be involved with filler induced malar edema - A duplex ultrasound-imaging-based case series. J Cosmet Dermatol. 2023 Dec;22(12):3246-3251.Tier 3Supports: Prospective case series of 17 patients (26 eyes) referred with malar oedema after hyaluronic acid filler treatment, all assessed with an 18 MHz linear ultrasound device. Onset ranged from immediate (0 days) to 3 years; 13 patients (76%) had early onset and 4 (24%) late onset. In 23 of 26 eyes filler material was located inside the SMAS; in 3 cases it was on the periosteum of the orbital rim. After duplex-ultrasound-guided filler removal, restored venous flow was seen in the superficial and/or deep fatty layer, often piercing through the SMAS, with clinical improvement of malar oedema observed within minutes. Authors conclude malar oedema after periocular filler 'may be caused by veno-lymphatic compression by filler deposits'. SCOPE: uncontrolled case series, n=17, referral population so selection-biased; mechanism is inferred from imaging plus response to removal, not proven. It does not test manual drainage, but it identifies the cause as a mechanical obstruction that drainage cannot relieve. DISCLOSURE, CORRECTED ON VERIFICATION: exactly ONE author (Shah-Desai) is affiliated with a commercial aesthetic practice (Perfect Eyes Ltd, London) - the earlier statement of 'two authors' was wrong. The other four authors list Erasmus University Medical Center and Queen Mary University of London. The paper's own declared conflict of interest is 'None' and no funding statement is recorded; readers should weigh that against a paper on filler complications authored partly from private aesthetic practice, where manufacturer consultancies are common in this field and none are declared here.Funding / interest: No funding statement recorded (Crossref lists no funder). Declared conflict of interest: 'None.'
  12. Department of Health and Social Care. The licensing of non-surgical cosmetic procedures in England (consultation document). GOV.UK, 2023 (consultation closed 28 October 2023; page updated 7 August 2025).Tier 1Supports: Proposed (not enacted) three-tier model. Green: 'procedures with the lowest risk of complications. All practitioners are eligible to perform licensed procedures where they meet agreed standards' - listed as microneedling, mesotherapy, IPL and LED therapies, superficial-only chemical peels, no-needle fillers, micropigmentation/microblading/nanoblading, non-ablative laser hair removal, photo rejuvenation. Amber: 'medium risk... Non-healthcare professionals must be licensed and have relevant oversight by a named regulated healthcare professional' - botulinum toxin, semi-permanent dermal fillers (face only), biorevitalisation, PRP, cryolipolysis, HIFU, radiofrequency, medium-depth peels and others. Red: 'highest risk... Can only be carried out by qualified and regulated healthcare professionals working out of CQC registered premises' - thread lifts, hair restoration surgery, deep chemical peels, CO2 lasers, IV injectables and others. Manual lymphatic drainage, massage and manual therapies are not named in any tier. The document excludes 'Face masks and other spa products that are not designed to penetrate the outermost layer of the skin'. Tier wording, tier contents, the 28 October 2023 closing date, the 7 August 2025 page update and the face-mask/spa exclusion were all re-verified verbatim against the live GOV.UK page on 1 August 2026. SCOPE: this is a consultation proposal only. No licensing scheme is in force in England as at August 2026, and the August 2025 consultation response does not itself assign procedures to tiers.Funding / interest: UK Department of Health and Social Care consultation document; no commercial funding.